Association of GP88 (progranulin) tumor expression with decreased disease-free and overall survivals in patients with breast cancer with estrogen receptor-positive invasive ductal carcinoma.

Context.— The 21-gene recurrence score (RS) provides a probability of distant recurrence for estrogen receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancers. The utility of RS for rarer histologic subtypes of breast cancer is uncertain. Objective.— To determine the distribution of RS among various histologic subtypes using a population database. Design.— Women between the ages of 18 and 75 with estrogen receptor-positive, HER2-negative breast cancer and known RS results were identified using the Surveillance, Epidemiology, and End Results database. Recurrence scores were categorized into risk groups using both traditional and Trial Assigning Individualized Options for Treatment cutoffs. Multivariable logistic regression was used to determine factors associated with high-risk RS. Results.— We identified 45 618 patients with stage I to III, estrogen receptor–positive, HER2-negative breast cancer who had RS available. Overall, 3087 (7%) and 6337 (14%) of cancers were classified as high risk based on traditional and Trial Assigning Individualized Options for Treatment RS cutoffs, respectively. The proportion of high-risk RS ranged from 1% (tubular, 2 of 225) to 68% (medullary, 13 of 19) and 4% (tubular, 10 of 225) to 79% (medullary, 15 of 19) for traditional and Trial Assigning Individualized Options for Treatment cutoffs, respectively. Based on multivariable logistic regression (excluding medullary), subtypes other than invasive ductal carcinoma and papillary carcinoma were significantly associated with lower RS. The strongest predictors of a high-risk RS were higher tumor grade and negative progesterone receptor status. Conclusions.— We identified distinct distributions of RS among different histologic subtypes of breast cancer. Excluding medullary carcinoma, histologic subtypes other than invasive ductal carcinoma and papillary carcinoma all predict lower RS.

Download Full-text

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Yearbook of Medicine ◽

10.1016/s0084-3873(12)00184-8 ◽

2012 ◽

Vol 2012 ◽

pp. 114-115

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Ductal Carcinoma In Situ ◽

Carcinoma In Situ ◽

Ductal Carcinoma ◽

Adjuvant Tamoxifen ◽

Estrogen Receptor Positive

Download Full-text

Survival with adjuvant surgical oophorectomy and tamoxifen in premenopausal women with operable breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.552 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 552-552 ◽

Cited By ~ 1

Author(s):

R. R. Love ◽

N. V. Dinh ◽

T. T. Quy ◽

N. D. Linh ◽

E. M. Hade ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Estrogen Receptor ◽

Adjuvant Therapy ◽

Premenopausal Women ◽

Operable Breast Cancer ◽

Primary Study ◽

Estrogen Receptor Positive ◽

Disease Free

552 Background: Reports of randomized trials evaluating adjuvant ovarian suppression or ablation with and without tamoxifen are limited in number, useful comparative data and long-term follow-up. Methods: From 1993–99 we recruited 709 Vietnamese and Chinese premenopausal women with clinical stage II-III operable breast cancer to a multi-site randomized prospective clinical trial of immediate pre-mastectomy adjuvant surgical oophorectomy followed by tamoxifen for 5 years (n=356) or mastectomy alone with the same combined hormonal therapy on recurrence of disease (n=353).The primary study endpoints were disease-free and overall survival.This report provides analyses for an extended follow-up period after 5 years. Results: With a median follow up of 7 years, disease-free and overall survival were significantly better with adjuvant therapy (log-rank p-values of 0.0003 and 0.0002). Ten year DFS probabilities of 62% and 51% (95%CI 4–22%), and OS probabilities of 70% and 52% (95% CI 6–34%) between adjuvant and observation groups were observed. In the estrogen receptor positive patient subset, 5 and 10 year DFS probabilities were 83% and 61%, and 66% and 47%; and 5 and 10 year OS probabilities were 88% and 74% and 82% and 74% in adjuvant and observation groups respectively. Conclusions: In women with estrogen receptor positive operable breast cancers, 5 and 10 year disease free and overall survival rates following adjuvant oophorectomy and tamoxifen compare favorably with those from other adjuvant regimens. In estrogen receptor positive patients, the hazard function with adjuvant therapy increases after year six. No significant financial relationships to disclose.

Download Full-text